This document discusses the different types of labels required for pharmaceutical products. It describes manufacturer labels, which contain drug information supplied by the manufacturer for medical professionals. Manufacturer labels must include the name, strength, dosage form, quantity, instructions, precautions, warnings, registration number, batch number, manufacturing and expiry dates, and manufacturer information. Dispensing labels contain additional information for patients, such as the patient's name, prescription number, directions for use, and pharmacy details. Proper labeling helps ensure drugs are used safely and effectively.
The highlights of this presentation covers importance of drug labeling, general labeling provisions, labeling requirements for prescription drugs and/or insulin, labeling requirements for over-the-counter (OTC) drugs, exemptions from adequate directions for use, and labeling claims for drugs in drug efficacy study.
This presentation contains legal requirements for labeling for pharmaceuticals, types of label, objective of label and recent advancement in labeling of pharmaceuticals.
Drug Information Services, Drug information Sources, Illegal DIC, Drug Information Bulletin, Classification of scientific literature, services offered bu drug information services
The highlights of this presentation covers importance of drug labeling, general labeling provisions, labeling requirements for prescription drugs and/or insulin, labeling requirements for over-the-counter (OTC) drugs, exemptions from adequate directions for use, and labeling claims for drugs in drug efficacy study.
This presentation contains legal requirements for labeling for pharmaceuticals, types of label, objective of label and recent advancement in labeling of pharmaceuticals.
Drug Information Services, Drug information Sources, Illegal DIC, Drug Information Bulletin, Classification of scientific literature, services offered bu drug information services
Dispensing of Prescription Rx & Ethic of Pharmacist with PatientsDashty Rihany
A prescription is an order form a registered practitioner or another properly licensed practitioner such as a physician, dentist, Doctor veterinarian or dermatologists etc. to a pharmacist to compound Pharmacy and dispense a specific medicine for the patient.
Drug distribution is one of the basic service provided by the hospital pharmacy.
Drug distribution system falls in to 3 categories -
1)Ward – controlled system
2)Pharmacy controlled imprest based system
3)Pharmacy controlled patient issue system
COMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).pptSumit Tiwari
A community pharmacy, often referred to as retail pharmacy or retail drug outlets, is places where medicines are stored and dispensed, supplied or sold
Dispensing of Prescription Rx & Ethic of Pharmacist with PatientsDashty Rihany
A prescription is an order form a registered practitioner or another properly licensed practitioner such as a physician, dentist, Doctor veterinarian or dermatologists etc. to a pharmacist to compound Pharmacy and dispense a specific medicine for the patient.
Drug distribution is one of the basic service provided by the hospital pharmacy.
Drug distribution system falls in to 3 categories -
1)Ward – controlled system
2)Pharmacy controlled imprest based system
3)Pharmacy controlled patient issue system
COMMUNITY PHARMACY AND MANAGEMENT – CHAPTER -1................... (1).pptSumit Tiwari
A community pharmacy, often referred to as retail pharmacy or retail drug outlets, is places where medicines are stored and dispensed, supplied or sold
This is to deal with UG Pharmacology entry label practical To know what are the various sources of drug information.
To select the appropriate source depending on the information.
To discuss briefly the role of electronic media in medicine.
pharmaceutical companies spend money to develop appropriate literature to market their new drugs. ppt throws light on how healthy skepticism will help the health care practitioners to interpret the literature presented by the medical representatives
This presentation covers the essential concept of ensuring all promotional communications are on label and the safe harbors established by FDA for disseminating off-label information compliantly.
The increased availability of biomedical data, particularly in the public domain, offers the opportunity to better understand human health and to develop effective therapeutics for a wide range of unmet medical needs. However, data scientists remain stymied by the fact that data remain hard to find and to productively reuse because data and their metadata i) are wholly inaccessible, ii) are in non-standard or incompatible representations, iii) do not conform to community standards, and iv) have unclear or highly restricted terms and conditions that preclude legitimate reuse. These limitations require a rethink on data can be made machine and AI-ready - the key motivation behind the FAIR Guiding Principles. Concurrently, while recent efforts have explored the use of deep learning to fuse disparate data into predictive models for a wide range of biomedical applications, these models often fail even when the correct answer is already known, and fail to explain individual predictions in terms that data scientists can appreciate. These limitations suggest that new methods to produce practical artificial intelligence are still needed.
In this talk, I will discuss our work in (1) building an integrative knowledge infrastructure to prepare FAIR and "AI-ready" data and services along with (2) neurosymbolic AI methods to improve the quality of predictions and to generate plausible explanations. Attention is given to standards, platforms, and methods to wrangle knowledge into simple, but effective semantic and latent representations, and to make these available into standards-compliant and discoverable interfaces that can be used in model building, validation, and explanation. Our work, and those of others in the field, creates a baseline for building trustworthy and easy to deploy AI models in biomedicine.
Bio
Dr. Michel Dumontier is the Distinguished Professor of Data Science at Maastricht University, founder and executive director of the Institute of Data Science, and co-founder of the FAIR (Findable, Accessible, Interoperable and Reusable) data principles. His research explores socio-technological approaches for responsible discovery science, which includes collaborative multi-modal knowledge graphs, privacy-preserving distributed data mining, and AI methods for drug discovery and personalized medicine. His work is supported through the Dutch National Research Agenda, the Netherlands Organisation for Scientific Research, Horizon Europe, the European Open Science Cloud, the US National Institutes of Health, and a Marie-Curie Innovative Training Network. He is the editor-in-chief for the journal Data Science and is internationally recognized for his contributions in bioinformatics, biomedical informatics, and semantic technologies including ontologies and linked data.
This pdf is about the Schizophrenia.
For more details visit on YouTube; @SELF-EXPLANATORY;
https://www.youtube.com/channel/UCAiarMZDNhe1A3Rnpr_WkzA/videos
Thanks...!
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
Richard's aventures in two entangled wonderlandsRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
Multi-source connectivity as the driver of solar wind variability in the heli...Sérgio Sacani
The ambient solar wind that flls the heliosphere originates from multiple
sources in the solar corona and is highly structured. It is often described
as high-speed, relatively homogeneous, plasma streams from coronal
holes and slow-speed, highly variable, streams whose source regions are
under debate. A key goal of ESA/NASA’s Solar Orbiter mission is to identify
solar wind sources and understand what drives the complexity seen in the
heliosphere. By combining magnetic feld modelling and spectroscopic
techniques with high-resolution observations and measurements, we show
that the solar wind variability detected in situ by Solar Orbiter in March
2022 is driven by spatio-temporal changes in the magnetic connectivity to
multiple sources in the solar atmosphere. The magnetic feld footpoints
connected to the spacecraft moved from the boundaries of a coronal hole
to one active region (12961) and then across to another region (12957). This
is refected in the in situ measurements, which show the transition from fast
to highly Alfvénic then to slow solar wind that is disrupted by the arrival of
a coronal mass ejection. Our results describe solar wind variability at 0.5 au
but are applicable to near-Earth observatories.
9. Manufacturer label
• A label which contain drug information for the use of
medical practitioners, pharmacists, or nurses
supplied by the manufacturer, packer, or distributor
of the drug
(FDA)
10. LEGAL REQUIRMENTS OF A
MANUFACTURER LABEL
1. The name of preparation
2. Strength and dosage form.
3. Quantity.
4. Instructions for the use.
5. Precautions & warnings.
6.Registration number.
7. Batch number.
8. Manufacturing & Expiry date .
9.Price
10.The name and address of pharmaceutical industry
11. NAME OF THE PREPARATION
Generic name:
According to drug labelling and packaging rules 1986:
“ International non-proprietary name means the
name of a drug as recommended by WHO or may be
notified by the federal govt. in the official gazette”
6-12
15. DOSAGE FORM
• Dosage form of the medicine should be mentioned on
the label. e.g.,
• Different dosage forms of Amoxicillin
16. QUANTITY
Quantity /volume present per a packaging unitQuantity /volume present per a packaging unit
The container hold 20 tablets and each tablet has
a dosage strength of 500 mg per tablet.
The container hold 20 tablets and each tablet has
a dosage strength of 500 mg per tablet.
26. Inflammable:
If the preparation contain 50% or more alcohol or any
other inflammable solvent, the label should contain
word inflammable
27. Not to be taken:
Liquid preparation that are not administered by mouth
For nasal drops, enemas and nasal sprays
Unit dosage forms e.g., pessaries and rectal suppositories
Help to administer drugs safely
Types of warnings
If hypersenstivity to a drug
For controlled substances
About combining with other drugs or products
6-28
28. Registration number
“A number given to a specific drug when it is
registered according to specific rules by registration
board set up by federal government”
29. Batch number
Acc. to drug act 1976
“A designation printed on label of a drug that
identifies the batch and permits the production
history of the batch including all stages of
manufacturer and control to be traced and are
viewed”
31. Expiry date
Accorrding to drug act 1976 S 3
“Date stated on the label of a drug after which a drug
is not expected to retain its claimed efficacy, safety,
quantity, or potency or after which it is no permissible
to sell the drug”
6-32
32. Liscense number
Biological products are approved for marketing under
the provisions of the Public Health Service (PHS) Act.
The Act requires a firm who manufactures a biologic
for sale in interstate commerce to hold a license for
the product
44. Interactions
• Certain drugs may have serious reactions if eat with
particular food or drugs,e.g:
a)Amine containing foods (tyrosine) with monoamine
oxidase inhibitors.(hypertension crises)
b)Tetracycline with milk
45. REFERENCES:
1. Mannual of drug laws 2014
2. Dispensing for pharmaceutical students pharmacy by S.J
Carter
6-46
